| (Values in U.S. Thousands) | Sep, 2018 | Jun, 2018 | Mar, 2018 | Dec, 2017 | Sep, 2017 |
| Sales | 42,470 | 42,600 | 38,430 | 21,300 | 0 |
| Sales Growth | -0.31% | +10.85% | +80.42% | unch | unch |
| Net Income | -27,060 | -11,730 | -3,560 | -20,630 | -73,320 |
| Net Income Growth | -130.69% | -229.49% | +82.74% | +71.86% | -141.18% |
Loxo Oncology CS (LOXO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Loxo Oncology, Inc. is a biopharmaceutical company. It develops targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Loxo Oncology, Inc. is headquartered in Stamford, Connecticut.
Fiscal Year End Date: 12/31